🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  2. CISPLATIN, BL-B01D1, GEMCITABINE, PEGFILGRASTIM, CARBOPLATIN

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  3. CISPLATIN, CARBOPLATIN, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, GEMCITABINE, IMJUDO 20 mg/ml concentrate for solution for infusion., INFLIXIMAB, GEMCITABINE

    AstraZeneca AB

    Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer

    phase 3 small molecule active

    1 trial

  4. CISPLATIN, FLUOROURACIL, MITOMYCIN, CAPECITABINE, CAPECITABINE, DOCETAXEL

    CERO THERAPEUTICS HOLDINGS, INC.

    locally advanced anal squamous cell carcinoma

    phase 3 small molecule active

    1 trial

  5. CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS, Placebo to Clostridium Botulinum neurotoxin type A (150 kD)

    Merz Therapeutics GmbH

    Episodic migraine

    phase 3 small molecule active

    1 trial

  6. CLS2901C (human [allogeneic] chondrocyte sheets)

    CellSeed Europe Ltd

    Osteoarthritis of the Knee

    phase 3 mab active

    1 trial

  7. CMF regimen

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 small molecule active

    2 trials

  8. COBALAMIN

    The George Institute

    Hydroxycobalamin deficiency

    phase 3 small molecule active

    1 trial

  9. COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial Infarction, Coronary Syndrome, Cerebral Infarction

    phase 3 small molecule active

    1 trial

  10. COMP360 psilocybin

    Compass Therapeutics

    PTSD - Post Traumatic Stress Disorder

    phase 3 small molecule active

    1 trial

  11. CONDROSULF 800 mg tabletta

    The George Institute

    Knee osteoarthritis with moderate to severe pain

    phase 3 small molecule active

    1 trial

  12. CONOXIA, gas medicinal comprimido, Conoxia 100% medicinal gas, cryogenic

    The George Institute

    ILD

    phase 3 small molecule active

    1 trial

  13. COPINAL 300 mg cápsulas, Placebo has the same composition than imp except the active substance

    The George Institute

    Chronic liver disease

    phase 3 small molecule active

    1 trial

  14. CORTANCYL 20 mg, comprimé sécable, Placebo of CORTANCYL 20 mg

    Pari Pharma GmbH

    Adults patients with isolated acute urticaria presenting to the emergency department

    phase 3 small molecule active

    1 trial

  15. CP101

    Finch Therapeutics Group

    Recurrent C. Difficile Infection

    phase 3 mab terminated

    1 trial

  16. CPI-0610, CPI-0610

    Novartis Pharmaceuticals

    Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)

    phase 3 small molecule active

    1 trial

  17. CRT with triple site ventricular stimulation

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 3 other completed

    1 trial

  18. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 other completed

    1 trial

  19. CTX-009

    Compass Therapeutics

    Biliary Tract Cancer

    phase 3 small molecule active

    1 trial

  20. CYCLOPHOSPHAMIDE

    Pari Pharma GmbH

    The study will involve adult women and men from 16 French centers who have hematological malignancies and are candidates for haploidentical HSCT

    phase 3 small molecule active

    1 trial

  21. CYCLOPHOSPHAMIDE, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, THIOTEPA, FLUDARABINE PHOSPHATE, TREOSULFAN, BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion., BUSULFAN, ETOPOSIDE

    The George Institute

    Acute Lymphoblastic Leukaemia

    phase 3 small molecule active

    1 trial

  22. CYCLOPHOSPHAMIDE, EPIRUBICIN, TRASTUZUMAB EMTANSINE, PACLITAXEL, DOXORUBICIN, DOCETAXEL, PACLITAXEL ALBUMIN-BOUND, TRASTUZUMAB, CARBOPLATIN, Phesgo 1200 mg/600 mg solution for injection, Phesgo 600 mg/600 mg solution for injection, TRASTUZUMAB, PERTUZUMAB

    The George Institute

    HER2-positive early breast cancer

    phase 3 small molecule active

    1 trial

  23. CaPre

    Grace Therapeutics

    Hypertriglyceridemia

    phase 3 small molecule completed

    2 trials

  24. Cadisegliatin 800 mg QD

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources